Cytosorbents Corp
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Insider Trading Arrangements
On June 13, 2025, Dr. Efthymios Deliargyris, our Chief Medical Officer, adopted a Rule 10b5-1 trading plan for the sale of the Company’s common stock. The plan, which has a term of one year, provides for the sale of up to 157,500 incentive stock options through market or limit orders.
Other than the individual disclosed above, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.